Cargando…

Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs and the Risk of Vascular Dementia in Patients with Spondyloarthritis: A Database Cohort Study

Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease that mainly affects the axial bones, and dementia is characterized by a decline in cognitive function, leading to dependence in everyday activity. Although the association between dementia and ankylosing spondylitis has been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yu-Hao, Huang, Shih-Wei, Chen, Chih-Kuang, Hong, Jia-Pei, Chen, Yi-Wen, Lin, Hui-Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917485/ https://www.ncbi.nlm.nih.gov/pubmed/36769598 http://dx.doi.org/10.3390/jcm12030950

Ejemplares similares

Do Tofacitinib Generics Exhibit Conventional Synthetic Disease-Modifying Anti-rheumatic Drug and Non-steroidal Anti-inflammatory Drug-Sparing Ability in the Management of Axial Spondyloarthritis?
por: Ganapati, Arvind, et al.
Publicado: (2023)

Attitudes and practices in the laboratory monitoring of conventional synthetic disease modifying anti-rheumatic drugs by rheumatologists and rheumatology trainees
por: Tsakas, James J., et al.
Publicado: (2022)

Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience
por: Migkos, Michalis P., et al.
Publicado: (2021)

Neoplasm Risk in Rheumatic Diseases Has No Correlation With Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs Usage—A Population-Based Nested Case–Control Study
por: Cai, Shaozhe, et al.
Publicado: (2020)

Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs
por: Rivellese, Felice, et al.
Publicado: (2020)

Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea
por: Ha, So-Young, et al.
Publicado: (2021)

Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs for Psoriatic Arthritis: Findings and Implications From a Patient Centered Longitudinal Study in Brazil
por: Faria, Ronaldo José, et al.
Publicado: (2022)

Elicitation of Rheumatologist Preferences for the Treatment of Patients with Rheumatoid Arthritis After the Failure of a First Conventional Synthetic Disease-Modifying Anti-Rheumatic Agent
por: Senbel, Eric, et al.
Publicado: (2021)

An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis
por: Tenti, Sara, et al.
Publicado: (2023)

Add-On Effects of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs in Ankylosing Spondylitis: Data from a Real-World Registered Study in China
por: Man, Siliang, et al.
Publicado: (2020)

Association between Autoimmune Rheumatic Diseases and the Risk of Dementia
por: Lu, Kang, et al.
Publicado: (2014)

Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease-modifying anti-rheumatic drugs: A meta-analysis of randomized controlled trials
por: Wu, Zhi-Peng, et al.
Publicado: (2018)

Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis
por: Choy, Ernest H
Publicado: (2019)

Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient
por: Sagnelli, Caterina, et al.
Publicado: (2020)

Tripterygium wilfordii Hook F versus conventional synthetic disease-modifying anti-rheumatic drugs as monotherapy for rheumatoid arthritis: a systematic review and network meta-analysis
por: Wang, Hai-Long, et al.
Publicado: (2016)

Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons
por: Akkoç, Nurullah, et al.
Publicado: (2023)

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs
por: Michelena, Xabier, et al.
Publicado: (2020)

Proteomic analysis of synovial fluid from rheumatic arthritis and spondyloarthritis patients
por: Birkelund, Svend, et al.
Publicado: (2020)

Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study
por: Convertino, Irma, et al.
Publicado: (2021)

Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials
por: Persson, Monica S M, et al.
Publicado: (2018)

Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis
por: G.S. Saad, Carla, et al.
Publicado: (2023)

Patients with Axial Spondyloarthritis Are at Risk of Developing Adhesive Capsulitis: Real-World Evidence Database Study in Taiwan
por: Huang, Shih-Wei, et al.
Publicado: (2020)

Rheumatoid arthritis serotype and synthetic disease-modifying anti-rheumatic drugs in patients with periodontitis: A case-control study
por: Nik-Azis, Nik-Madihah, et al.
Publicado: (2021)

Conventional disease-modifying anti-rheumatic drugs combined with Chinese Herbal Medicines for rheumatoid arthritis: A systematic review and meta-analysis
por: Han, Rong, et al.
Publicado: (2022)

Tuberculosis in Children with Rheumatic Diseases Treated with Biologic Disease-Modifying Anti-Rheumatic Drugs
por: Kavadichanda, Chengappa, et al.
Publicado: (2021)

A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients
por: Tian, Feng, et al.
Publicado: (2019)

Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus
por: Chen, Sarah K, et al.
Publicado: (2020)

COVID-19 and Disease-Modifying Anti-rheumatic Drugs
por: D’Silva, Kristin M., et al.
Publicado: (2021)

The effect of uveitis and undiagnosed spondyloarthritis: a systematic review and meta-analysis
por: Lee, Shih-Ching, et al.
Publicado: (2023)

Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis
por: Su, Yu-Jih, et al.
Publicado: (2023)

Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis
por: Koo, Bon San, et al.
Publicado: (2022)

Effectiveness and safety of 99Tc-methylene diphosphonate as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional synthetic (cs) DMARDs in the treatment of rheumatoid arthritis: A systematic review and meta-analysis of 34 randomized controlled trials
por: Deng, Guoqian, et al.
Publicado: (2023)

Peptide-Modified Zwitterionic Porous Hydrogels for Endothelial Cell and Vascular Engineering
por: Lin, Chih-Yeh, et al.
Publicado: (2014)

Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs
por: Moradi, Soroush, et al.
Publicado: (2020)

Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs
por: Nakafero, Georgina, et al.
Publicado: (2020)

Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs
por: Yousefghahari, Behnaz, et al.
Publicado: (2021)

Diagnostic value of anti-Kaiso autoantibody in axial spondyloarthritis
por: Feng, Xinzhe, et al.
Publicado: (2023)

Characteristics of Late-Onset Spondyloarthritis: Data from the Moroccan Registry of Biological Therapies in Rheumatic Diseases
por: Mougui, Ahmed, et al.
Publicado: (2023)

Recent Advancements in Drug Delivery of Sinomenine, A Disease-Modifying Anti-Rheumatic Drug
por: Chen, Xin, et al.
Publicado: (2022)

Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
por: Lubrano, Ennio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qbg89p0fr9qrnntpmhl0i7cscg